Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of Clinical Oncology

• Publication date

  2012-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2011.39.8446PMID 22851566PMCID PMC3732004
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221)

  2011cited by this paper
• Genetic associations with taxane-induced neuropathy by a genome-wide association study (GWAS) in E5103.

  2011cited by this paper
• Inherited genetic variation in EPHA5, FGD4, and NRDG1 and paclitaxel (P)-induced peripheral neuropathy (PN): Results from a genome-wide association study (GWAS) in CALGB 40101.

  2010cited by this paper
• Paclitaxel-Related Peripheral Neuropathy Associated with Improved Outcome of Patients with Early Stage HER2+ Breast Cancer Who Did Not Receive Trastuzumab in the N9831 Clinical Trial.

  2009cited by this paper
• San Antonio Breast Cancer Symposium.

  2009cited by this paper
• Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.

  2008cited by this paper
• Weekly paclitaxel in the adjuvant treatment of breast cancer.

  2008cited by this paper
• Microtubule stabilization specifies initial neuronal polarization

  2008cited by this paper
• Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies.

  2008cited by this paper
• Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management.

  2008cited by this paper
• Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies.

  2008cited by this paper
• An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat.

  2007cited by this paper
• Benefit of taxanes as adjuvant chemotherapy for early breast cancer

  2006cited by this paper
• Studies of peripheral sensory nerves in paclitaxel‐induced painful peripheral neuropathy: Evidence for mitochondrial dysfunction

  2006cited by this paper
• Sensory neurons and their supporting cells located in the trigeminal, thoracic and lumbar ganglia differentially express markers of injury following intravenous administration of paclitaxel in the rat.

  2006cited by this paper
• Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.

  2006cited by this paper
• Peripheral neuropathy induced by microtubule-stabilizing agents.

  2006cited by this paper
• Adjuvant docetaxel for node-positive breast cancer.

  2005cited by this paper
• Adjuvant docetaxel for node-positive breast cancer.

  2005cited by this paper
• Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

  2005cited by this paper
• Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer.

  2005cited by this paper
• Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats.

  2005cited by this paper
• Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

  2003cited by this paper
• Weekly, high‐dose paclitaxel in advanced lung carcinoma

  2003cited by this paper
• Taxol impairs anterograde axonal transport of microinjected horseradish peroxidase in dorsal root ganglia neurons in vitro

  2000cited by this paper
• Morphological evidence of the inhibitory effect of taxol on the fast axonal transport.

  1999cited by this paper
• The impact of diabetes mellitus on the toxicity of therapy for advanced ovarian cancer.

  1996cited by this paper
• Experimental peripheral neuropathy induced in adult rats by repeated intraperitoneal administration of taxol.

  1995cited by this paper
• Clinical toxicities encountered with paclitaxel (Taxol).

  1993cited by this paper
• Neurotoxicity of Taxol.

  1993cited by this paper
• Microtubule-mitochondrial associations in regenerating axons after taxol intoxication

  1987cited by this paper

• Addressing the Needs of Breast Cancer Survivors

  2025cites this paper
• Review of the Contribution of Clinical and Genetic Factors to the Racial Disparity in Taxane-Induced Peripheral Neuropathy.

  2025cites this paper
• Association between hyperglycemia and the development of chemotherapy induced peripheral neuropathy among patients with breast cancer in the control trial

  2025cites this paper
• Efficacy of Mirogabalin for Taxane-associated Chemotherapy-induced Peripheral Neuropathy in Perioperative Chemotherapy for Early Breast Cancer

  2024cites this paper
• Chemotherapy-Induced Peripheral Neuropathy (CIPN): A Narrative Review and Proposed Theoretical Model

  2024cites this paper
• Conditioned Medium of Mesenchymal Stromal Cells Loaded with Paclitaxel Is Effective in Preclinical Models of Triple-Negative Breast Cancer (TNBC)

  2023cites this paper
• Chemotherapy-induced peripheral neurotoxicity: single-centre prospective study

  2023cites this paper
• CYP3A genetic variation and taxane-induced peripheral neuropathy: a systematic review, meta-analysis, and candidate gene study

  2023cites this paper
• Incidence, description, predictors, and consequences of persistent taxane-induced peripheral neuropathy

  2023cites this paper
• Correlates of Taxane-Induced Neuropathy, an Electronic Health Record Based Observational Study

  2023cites this paper
• The Clinical Effect of Triglyceride Glucose Index, an Insulin Resistance Marker, in Predicting Neuropathy Induced by the FOLFOX Chemotherapy Protocol

  2022cites this paper
• Ovariectomy increases paclitaxel-induced mechanical hypersensitivity and reduces anti-inflammatory CD4+ T cells in the dorsal root ganglion of female mice

  2022cites this paper
• The Clinical Effect of Triglyceride Glucose index, an insulin Resistance Marker, on Predicting Paclitaxel-induced Neuropathy

  2022cites this paper
• The effect of trastuzumab on taxane-induced peripheral neuropathy in women with breast cancer: a population-based cohort study

  2022cites this paper
• Drug treatment for chemotherapy-induced peripheral neuropathy in patients with pancreatic cancer

  2022cites this paper
• Serum sodium ions and chloride ions associated with taxane-induced peripheral neuropathy in Chinese patients with early-stage breast cancer: A nation-wide multicenter study

  2022cites this paper
• Neuropathic pain prevalence and risk factors in head and neck cancer survivors

  2022cites this paper
• Incidence density and factors associated with peripheral neuropathy among women with breast cancer during taxane-based chemotherapy

  2022cites this paper
• Prevalence and predictors of peripheral neuropathy after breast cancer treatment

  2021cites this paper
• The impact of obesity on neuropathy outcomes for paclitaxel- and oxaliplatin-treated cancer survivors

  2021cites this paper
• Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review

  2021influential citation
• Chemotherapy-Induced Neuropathy and Diabetes: A Scoping Review

  2021influential citation
• Association between Low-Grade Chemotherapy-Induced Peripheral Neuropathy (CINP) and Survival in Patients with Metastatic Adenocarcinoma of the Pancreas

  2021cites this paper
• Chemotherapy‐induced peripheral neuropathy in African American cancer survivors: Risk factors and quality of life outcomes

  2021cites this paper
• Impact of Genetic Ancestry on Treatment Toxicity and Racial Disparities in Breast Cancer

  2020cites this paper
• Presence and Distress of Chemotherapy-Induced Peripheral Neuropathy Symptoms in Upper Extremities of Younger and Older Breast Cancer Survivors.

  2020cites this paper
• Patient‐reported and clinician‐reported chemotherapy‐induced peripheral neuropathy in patients with early breast cancer: Current clinical practice

  2019cites this paper
• Effect of cryotherapy on dose of adjuvant paclitaxel in early-stage breast cancer

  2019cites this paper
• Mexican Consensus on diagnosis and treatment of breast cancer

  2019cites this paper
• Consenso Mexicano sobre diagnóstico y tratamiento del cáncer mamario. Octava revisión. Colima 2019

  2019cites this paper
• A longitudinal examination of associations between age and chemotherapy-induced peripheral neuropathy in patients with gynecologic cancer.

  2019cites this paper
• Taxane and epothilone‐induced peripheral neurotoxicity: From pathogenesis to treatment

  2019influential citation
• Late side effects of adjuvant treatment in patients with breast cancer

  2019cites this paper
• Deleterious Effects of Higher Body Mass Index on Subjective and Objective Measures of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors.

  2019cites this paper
• Role of Germline Genetics in Identifying Survivors at Risk for Adverse Effects of Cancer Treatment.

  2018cites this paper
• Incidence and disease burden of chemotherapy-induced peripheral neuropathy in a population-based cohort

  2018cites this paper
• Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715)

  2018cites this paper
• Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30

  2018cites this paper
• Pre-treatment anxiety is associated with persistent chemotherapy-induced peripheral neuropathy in women treated with neoadjuvant chemotherapy for breast cancer.

  2018cites this paper
• Cancer Neurology in Clinical Practice

  2018cites this paper
• Colored body images reveal the perceived intensity and distribution of pain in women with breast cancer treated with adjuvant taxanes: a prospective multi-method study of pain experiences

  2018cites this paper
• The Influence of Chemotherapy-Induced Peripheral Neuropathy on Quality of Life of Gynecologic Cancer Survivors

  2018cites this paper
• Phenotypic Characterization of Paclitaxel-Induced Peripheral Neuropathy in Cancer Survivors.

  2018cites this paper
• The evaluation of changes in peripheral neuropathy and quality-of-life using low-frequency electrostimulation in patients treated with chemotherapy for breast cancer: a study protocol

  2018cites this paper
• Neurological Complications of Breast Cancer and Its Treatment

  2018cites this paper
• Evaluating local skin heating as an early detection method for small-fiber neuropathy in women with breast cancer receiving paclitaxel (Taxol®)

  2018cites this paper
• Taxane-induced pain : Experiences of women with breast cancer and nurses providing their care

  2018cites this paper
• Estrogen receptor-α promoter methylation is a biomarker for outcome prediction of cisplatin resistance in triple-negative breast cancer

  2017cites this paper
• BMI, Lifestyle Factors and Taxane‐Induced Neuropathy in Breast Cancer Patients: The Pathways Study

  2017cites this paper
• Fit for Chemo: Nerves May Thank You.

  2017cites this paper
• Incidence of taxane-induced peripheral neuropathy receiving treatment and prescription patterns in patients with breast cancer

  2017cites this paper
• BMI, Lifestyle Factors and Taxane-Induced Neuropathy in Breast Cancer Patients: The Pathways Study.

  2017cites this paper
• Fit for Chemo: Nerves May Thank You.

  2017cites this paper
• Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review

  2017cites this paper
• The early onset of peripheral neuropathy might be a robust predictor for time to treatment failure in patients with metastatic breast cancer receiving chemotherapy containing paclitaxel

  2017cites this paper
• Efficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer "in a Korean" population: A single-center cohort study.

  2017cites this paper
• Taxane-induced peripheral sensorial neuropathy in cancer patients is associated with duration of diabetes mellitus: a single-center retrospective study

  2016cites this paper
• Vincristine-induced peripheral neuropathy in pediatric cancer patients.

  2016cites this paper
• Peripheral neuropathy with microtubule inhibitor containing antibody drug conjugates: Challenges and perspectives in translatability from nonclinical toxicology studies to the clinic.

  2016cites this paper
• Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk

  2016cites this paper
• Charcot-Marie-Tooth gene, SBF2, associated with taxane-induced peripheral neuropathy in African Americans

  2016cites this paper
• Medikamentöse Behandlung gastrointestinaler Tumoren

  2016cites this paper
• Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials.

  2016cites this paper
• Delayed recovery and increased severity of Paclitaxel-induced peripheral neuropathy in patients with diabetes.

  2015cites this paper
• A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities

  2015cites this paper
• Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer

  2015cites this paper
• nested cohort

  2015cites this paper
• Targeting Histone Abnormality in Triple-Negative Breast Cancer

  2015cites this paper
• Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199

  2015influential citation
• No pain, no gain: a fallacy so far.

  2015cites this paper
• Docetaxel-induced neuropathy: A pharmacogenetic case-control study of 150 women with early-stage breast cancer

  2015cites this paper
• Neurotoxic 1‐deoxysphingolipids and paclitaxel‐induced peripheral neuropathy

  2015cites this paper
• Long term side effects of adjuvant chemotherapy in patients with early breast cancer.

  2015cites this paper
• Taxane-Induced Peripheral Neurotoxicity

  2015cites this paper
• The impact of diabetes on neuropathic symptoms and receipt of chemotherapy among colorectal cancer patients: results from the PROFILES registry

  2015cites this paper
• Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives

  2015cites this paper
• Léčivy indukované periferní neuropatie

  2014cites this paper
• Association between treatment toxicity and outcomes in oncology clinical trials.

  2014cites this paper
• Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy

  2014cites this paper
• Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline.

  2014cites this paper
• Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience

  2014cites this paper
• Impact of Obesity, Race, and Ethnicity on Cancer Survivorship

  2014cites this paper
• Early and late long-term effects of adjuvant chemotherapy.

  2013cites this paper
• Predictive Biomarkers and Personalized Medicine CYP 3 A 4 22 Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity

  2013cites this paper
• Treatment with Paclitaxel Orotate and Carboxyamidotriazole Orotate in SC-Implanted OVCAR-5 Human Ovarian Tumor Xenografts

  2013cites this paper
• Pharmacogenetic predictors of taxane-induced peripheral neuropathy

  2013influential citation
• Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer.

  2013cites this paper
• Axillary versus sentinel-lymph-node dissection for micrometastatic breast cancer.

  2013cites this paper
• Current World Literature

  2013cites this paper
• CYP3A4*22 Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity

  2013cites this paper
• Risk of docetaxel-induced peripheral neuropathy among 1,725 Danish patients with early stage breast cancer

  2013cites this paper
• Metastatic breast cancer epidemiology and management with a focus on taxanes.

  2013cites this paper
• CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel.

  2013influential citation
• Cumulative Genetic Risk Predicts Platinum/Taxane-Induced Neurotoxicity

  2013cites this paper
• Challenges of guarantee-time bias.

  2013cites this paper
• Impact of obesity on cancer survivorship and the potential relevance of race and ethnicity.

  2013cites this paper
• Linking toxicity to the target.

  2012cites this paper
• Cyp2c8*3 Increases Risk of Neuropathy in Breast Cancer Patients Treated with Paclitaxel † Original Articles Annals of Oncology

  year unknowncites this paper